within Pharmacolibrary.Drugs.ATC.V;

model V09AX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0038333333333333336,
    adminDuration  = 600,
    adminMass      = 0.37,
    adminCount     = 1,
    Vd             = 0.010199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Flortaucipir (18F) is a radioactive diagnostic agent used in positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease. It is an approved diagnostic radiopharmaceutical, not used as a therapeutic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters were reported in healthy volunteers and patients with cognitive impairment during and after a standard intravenous bolus injection. Key PK parameters were reported from dynamic PET studies.</p><h4>References</h4><ol><li><p>Golla, SSV, et al., &amp; Yaqub, M (2017). Quantification of Tau Load Using [. <i>Molecular imaging and biology</i> 19(6) 963–971. DOI:<a href=&quot;https://doi.org/10.1007/s11307-017-1080-z&quot;>10.1007/s11307-017-1080-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28374171/&quot;>https://pubmed.ncbi.nlm.nih.gov/28374171</a></p></li><li><p>Huang, YY, et al., &amp; Shiue, CY (2019). An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans. <i>PloS one</i> 14(7) e0217384–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0217384&quot;>10.1371/journal.pone.0217384</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31260447/&quot;>https://pubmed.ncbi.nlm.nih.gov/31260447</a></p></li><li><p>Gao, C, et al., &amp; Gao, C (2020). T807-modified human serum albumin biomimetic nanoparticles for targeted drug delivery across the blood-brain barrier. <i>Journal of drug targeting</i> 28(10) 1085–1095. DOI:<a href=&quot;https://doi.org/10.1080/1061186X.2020.1777420&quot;>10.1080/1061186X.2020.1777420</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32614677/&quot;>https://pubmed.ncbi.nlm.nih.gov/32614677</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09AX07;
